التداخل بين لينزوليد وريزاتريبتان

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors.

Plasma concentrations of rizatriptan may be increased by drugs that are selective MAO-A inhibitors (e.g., moclobemide) or nonselective MAO inhibitors [type A and B] (e.g., isocarboxazid, phenelzine, tranylcypromine, and pargyline).

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] .

Drug Interactions [See also Drug Interactions (7) .] Monoamine oxidase inhibitors : Rizatriptan is principally metabolized via monoamine oxidase, 'A' subtype (MAO-A).

The interaction would be expected to be greater with irreversible MAO inhibitors.

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome.

If signs or symptoms of serotonin syndrome occur, consider discontinuing Linezolid injection and/or concomitant serotonergic agents.

Serotonin Syndrome Spontaneous reports of serotonin syndrome including fatal cases associated with the concomitant use of linezolid and serotonergic agents have been reported.

Monitor patients for the emergence of serotonin syndrome with the concomitant use of Linezolid injection and serotonergic agents or with use of Linezolid injection in patients with carcinoid syndrome.

Inform patients of the increased risk of serotonin syndrome when Linezolid injection is used concomitantly with serotonergic agents.